288-90-4

Usage

Uses

Used in Biological Studies:
1,2,4-Oxadiazole is used as a compound in the biological study of antitubercular activity of butyrate-specific oxadiazoles against Mycobacterium tuberculosis and their cytotoxicity on monkey kidney cells. This application is significant for the development of new antitubercular drugs and understanding the potential side effects on other cells.
Used in Pharmaceutical Industry:
1,2,4-Oxadiazole is used as a building block for the synthesis of various pharmaceutical compounds due to its unique chemical properties and reactivity. The ability to form 3,5-disubstituted 1,2,4-oxadiazoles makes it a versatile component in the design and synthesis of new drugs with potential applications in various therapeutic areas.
Used in Chemical Research:
1,2,4-Oxadiazole is used as a subject of study in chemical research to understand its physical properties, such as its stability, reactivity, and the chemical shifts observed in the 13C NMR spectra. This knowledge can be applied to improve the synthesis methods and explore new applications for 1,2,4-oxadiazole and its derivatives in various industries.

InChI:InChI=1/C2H2N2O/c1-3-2-5-4-1/h1-2H

Upstream product

• 1679-64-7 Monomethyl terephthalate 

Relevant academic research and scientific papers

Lipopeptide Compounds and Their Use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.

Trisubstituted heterocyclic compounds and their use as fungicides

Compounds of general formula (I): in which:Het represents a five or six membered saturated, partially unsaturated or aromatic ring containing between one and six heteroatoms of the group N, O, S, in which the heterocycle is substituted in an adjacent manner with -P-Q1-T-Q2, -GZ and Y, such that the substituant -GZ is adjacent to both. the other substituants being as defined in the description,process for preparing these compounds,fungicidal compositions comprising these compounds,processes for treating plants by applying these compounds or compositions.

Substituted amino methyl factor Xa inhibitors

The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Oxazole PPAR antagonist

A method is disclosed for rational design of a PPAR, FXR, LXR-alpha, or LXR-beta antagonist comprising chemical modification of a PPAR, FXR, LXR-alpha, or LXR-beta agonist to: a) prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist bound position. Preferably, little or no additional changes are made in the structure of the agonist so that the resulting antagonist is a close structural analogue of the agonist. Specific examples of PPAR gamma antagonists designed and prepared using the method of this invention are compounds of Formula (I) or (II), or pharmaceutically acceptable salts or solvates thereof, where in Formula (I) X is O, S, or NH; and R is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, phenyl, or —CH2OCH3and wherein in Formula (II) X is C or N; and R is methyl, ethyl, n-propyl, i-propyl, —CH2OCH3, or —CO2CH3.

Heteroaryl-phenyl substituted factor Xa inhibitors

The present application describes heteroaryl-phenyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of factor Xa.

Heteroaryl- phenyl heterobicyclic factor Xa inhibitors

The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa

The present application describes inhibitors of factor Xa of formula I: or pharmaceutically acceptable salt forms thereof, wherein W, W1, W2, and W3may be N or C and J, Ja, and Jbcombine to form a substituted carbocycle or heterocycle.

6-membered aromatics as factor Xa inhibitors

The present application describes 6-membered aromatics of formula I: or pharmaceutically acceptable salt forms thereof, wherein D may be CH2NH2 or C(=NH)NH2, which are useful as inhibitors of factor Xa.

N-(AMIDINOPHENYL) CYCLOUREA ANALOGS AS FACTOR XA INHIBITORS

The present application describes N-(amidinophenyl)cyclourea analogs of formula I: STR1 which are useful as inhibitors of factor Xa.

INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP

The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: STR1 or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.